Zoetis Inc. Operating Lease, Expense
Zoetis Inc. (ZTS) reported Operating Lease, Expense of $68.00 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-02-12.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:OperatingLeaseExpense · last filed 2026-02-12
- Zoetis Inc. operating lease, expense for the quarter ending 2020-03-31 was $11.00M, a 22.22% increase year-over-year.
- Zoetis Inc. operating lease, expense for the quarter ending 2019-12-31 was $11.00M.
- Zoetis Inc. operating lease, expense for the quarter ending 2019-09-30 was $10.00M.
- Zoetis Inc. operating lease, expense for the quarter ending 2019-06-30 was $10.00M.
- Zoetis Inc. operating lease, expense for fiscal 2025 was $68.00M, a 15.25% increase from fiscal 2024.
- Zoetis Inc. operating lease, expense for fiscal 2024 was $59.00M, a 5.36% increase from fiscal 2023.
- Zoetis Inc. operating lease, expense for fiscal 2023 was $56.00M, a 9.80% increase from fiscal 2022.
- Zoetis Inc. operating lease, expense for fiscal 2022 was $51.00M, a 2.00% increase from fiscal 2021.
| Period end | Operating Lease, Expense 3 month | Operating Lease, Expense 6 month | Operating Lease, Expense 9 month | Operating Lease, Expense 12 month |
|---|---|---|---|---|
| 2025-12-31 | $68.00M 10-K · filed 2026-02-12 | |||
| 2024-12-31 | $59.00M 10-K · filed 2026-02-12 | |||
| 2023-12-31 | $56.00M 10-K · filed 2026-02-12 | |||
| 2022-12-31 | $51.00M 10-K · filed 2025-02-13 | |||
| 2021-12-31 | $50.00M 10-K · filed 2024-02-13 | |||
| 2020-12-31 | $46.00M 10-K · filed 2023-02-14 | |||
| 2020-03-31 | $11.00M 10-Q · filed 2020-05-06 | $22.00M derived: sum of 2 quarters · filed 2022-02-15 | $32.00M derived: sum of 3 quarters · filed 2022-02-15 | $42.00M derived: sum of 4 quarters · filed 2022-02-15 |
| 2019-12-31 | $11.00M derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-15 | $21.00M derived: sum of 2 quarters · filed 2022-02-15 | $31.00M derived: sum of 3 quarters · filed 2022-02-15 | $40.00M 10-K · filed 2022-02-15 |
| 2019-09-30 | $10.00M 10-Q · filed 2019-11-07 | $20.00M derived: sum of 2 quarters · filed 2019-11-07 | $29.00M 10-Q · filed 2019-11-07 | |
| 2019-06-30 | $10.00M 10-Q · filed 2019-08-06 | $19.00M 10-Q · filed 2019-08-06 | ||
| 2019-03-31 | $9.00M 10-Q · filed 2020-05-06 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |
| Viatris Inc (VTRS) | United States | $20.008B | -0.00 |
| Jazz Pharmaceuticals plc (JAZZ) | $15.333B | 16.07 | |
| Summit Therapeutics Inc. (SMMT) | United States | $13.071B | -13.21 |
| BridgeBio Pharma, Inc. (BBIO) | United States | $12.947B | -20.72 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |